Skip to main content

Table 2 Selected multivariable predictors of fast CKD progression over 24 months among adults with eGFR 30 to 59 ml/min/1.73 m2 stratified by baseline diabetes status

From: Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus

Characteristic

Adjusteda Odds Ratio (95% Confidence Interval) for Fast Progression in Adults with Stage 3 CKD and no Diabetes

N = 23,021

Adjustedb Odds Ratio (95% Confidence Interval) for Fast Progression in Adults with Stage 3 CKD and Diabetes

N = 13,174

Age group at study entry, yr

 18–49

1.16 (0.91–1.48)

1.60 (1.22–2.10)

 50–59

0.72 (0.61–0.86)

1.16 (1.00–1.34)

 60–69

0.81 (0.73–0.90)

1.03 (0.92–1.14)

 70–79

Reference

Reference

 ≥ 80

1.25 (1.14–1.36)

1.16 (1.03–1.30)

Male vs. female gender

1.00 (0.92–1.08)

0.99 (0.91–1.08)

Race

 White/European

Reference

Reference

 Black/African American

1.02 (0.90–1.16)

1.00 (0.88–1.14)

 Asian/Pacific Islander

1.00 (0.88–1.15)

1.02 (0.91–1.15)

 Native American

1.57 (0.81–3.04)

1.22 (0.67–2.20)

 Other

1.26 (0.68–2.34)

1.24 (0.81–1.92)

 Unknown

0.88 (0.69–1.11)

1.15 (0.94–1.42)

Hispanic ethnicity

1.05 (0.90–1.21)

1.03 (0.90–1.18)

Current/former smoking

1.21 (1.12–1.30)

–

Medical history

 Heart failure

1.77 (1.57–1.99)

1.58 (1.40–1.79)

 Ischemic stroke

1.50 (1.11–2.04)

–

 Pacemaker

1.43 (1.06–1.92)

–

 Proteinuria

1.86 (1.65–2.10)

2.31 (2.10–2.55)

 Valvular heart disease

–

0.86 (0.71–1.03)

Systolic blood pressure, mmHg

 ≤ 120

Reference

Reference

 121–129

1.17 (1.04–1.30)

1.14 (1.01–1.29)

 130–139

1.28 (1.15–1.41)

1.23 (1.08–1.39)

 140–159

1.44 (1.28–1.62)

1.47 (1.29–1.68)

 160–179

2.07 (1.75–2.46)

1.99 (1.64–2.42)

 ≥ 180

2.42 (1.80–3.24)

2.21 (1.59–3.08)

 Unknown

1.12 (0.88–1.43)

1.20 (0.94–1.53)

Laboratory values

 Hemoglobin, g/dL

  ≥ 13.0

Reference

Reference

  12.0–12.9

1.38 (1.25–1.53)

1.39 (1.23–1.56)

  11.0–11.9

2.02 (1.78–2.29)

1.63 (1.43–1.87)

  10.0–10.9

2.09 (1.73–2.54)

1.76 (1.47–2.11)

  9.0–9.9

1.46 (1.02–2.10)

2.09 (1.55–2.81)

  < 9.0

1.44 (0.85–2.43)

2.15 (1.26–3.68)

  Unknown

1.13 (1.01–1.26)

1.15 (1.02–1.30)

 HDL cholesterol, mg/dL

  ≥ 60

Reference

–

  50–59

1.09 (0.97–1.23)

–

  40–49

1.16 (1.04–1.30)

–

  35–39

1.25 (1.08–1.45)

–

  < 35

1.27 (1.07–1.50)

–

  Unknown

1.20 (1.07–1.36)

–

 LDL cholesterol, mg/dL

  ≥ 200

–

Reference

  160–199

–

1.73 (1.06–2.84)

  130–159

–

1.07 (0.80–1.44)

  100–129

–

1.10 (0.89–1.35)

  70–99

–

1.03 (0.90–1.17)

  < 70

–

0.93 (0.84–1.02)

  Unknown

–

1.07 (0.82–1.39)

  1. aAdjusted also for baseline level of eGFR and receipt of angiotensin II receptor blockers and calcium channel blockers at entry
  2. bAdjusted also for baseline level of eGFR and receipt of diuretics, calcium channel blockers and hydralazine at entry